During the last session, Seneca Biopharma, Inc. (NASDAQ:SNCA)’s traded shares were 1,295,811, with the beta value of the company hitting 1.88. At the end of the trading day, the stock’s price was $1.73, reflecting an intraday loss of -8.47% or -$0.16. The 52-week high for the SNCA share is $2.67, that puts it down -54.34% from that peak though still a striking +71.1% gain since the share price plummeted to a 52-week low of $0.5. The company’s market capitalization is $29.92 Million, and the average intraday trading volume over the past 10 days was 1.04 Million shares, and the average trade volume was 4.13 Million shares over the past three months.
Seneca Biopharma, Inc. (SNCA) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 0. SNCA has a Sell rating from none of the analyst(s) out of 1 analysts who have looked at this stock. Neither of the analyst(s) recommend to Hold the stock while none of them suggest Overweight, and 1 recommend a Buy rating for it. None of the analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be $0.
Seneca Biopharma, Inc. (NASDAQ:SNCA): Trading Information
Seneca Biopharma, Inc. (SNCA) registered a -8.47% downside in the last session and has traded in the green over the past 5 sessions. The stock spiked 8.47% in intraday trading to $1.89 this Tuesday, Apr 06, hitting a weekly high. The stock’s 5-day price performance is 5.49%, and it has moved by 45.38% in 30 days. Based on these gigs, the overall price performance for the year is 96.59%. The short interest in Seneca Biopharma, Inc. (NASDAQ:SNCA) is 530.64 Million shares and it means that shorts have 128.48 day(s) to cover.
The consensus price target of analysts on Wall Street is $520, which implies an increase of 29957.8% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $520 and $520 respectively. As a result, SNCA is trading at a discount of 29957.8% off the target high and 29957.8% off the low.
Seneca Biopharma, Inc. (SNCA) projections and forecasts
Revenue for the current quarter is expected to be $3Million as predicted by 1 analyst(s). Meanwhile, a consensus of 1 analyst(s) estimates revenue growth to $253Million by the end of May 2021. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $3Million and $8Million respectively. In this case, analysts expect current quarter sales to lessen by 0% and then jump by 3062.5% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 54.4%. While earnings are projected to return 69.1% in 2021, the next five years will return 0% per annum.
Seneca Biopharma, Inc. (NASDAQ:SNCA)’s Biggest Investors
Seneca Biopharma, Inc. insiders own 0.82% of total outstanding shares while institutional holders control 13.61%, with the float percentage being 13.72%. Renaissance Technologies, LLC is the largest shareholder of the company, while 28 institutions own stock in it. As of Dec 30, 2020, the company held over 167.51 Thousand shares (or 0.97% of all shares), a total value of $147.41 Thousand in shares.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The next largest institutional holding, with 123.56 Thousand shares, is of Virtu Financial LLC’s that is approximately 0.71% of outstanding shares. At the market price on Dec 30, 2020, these shares were valued at $108.73 Thousand.
Also, the Mutual Funds coming in first place with the largest holdings of Seneca Biopharma, Inc. (SNCA) shares are Fidelity Extended Market Index Fund and Vanguard Extended Market Index Fund. Data provided on Feb 27, 2021 indicates that Fidelity Extended Market Index Fund owns about 117,971 shares. This amounts to just over 0.68 percent of the company’s overall shares, with a $158.08 Thousand market value. The same data shows that the other fund manager holds slightly less at 8.28 Thousand, or about 0.05% of the stock, which is worth about $7.28 Thousand.